Summary

• 100% technical buy signals.
• 10 new highs and up 19.34% in the last month.
• 94.52% gain in the last year.

The Barchart Chart of the Day belongs to the biomedical company Bicycle Therapeutics (Nasdaq: BCYC). Readers are always asking me how to find stocks that are just beginning to trend before everyone else discovers them. One of the best ways is to look at Barchart's Strong Volume Gains preformatted screener. It identifies stocks that have had significant increases in both volume and price over the past 5 days. Today it identified 28 stocks that fitted that criteria. I sorted that list by the highest number of new highs in the last month then used the Flipchart feature to review the chart for consistent price appreciation. Since the Trend Spotter signaled a buy in 6/25 the stock gained 13.45%.  

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/IIa clinical trial targeting EphA2; BT8009, which is in preclinical studies targeting Nectin-4; and CD137, an immune cell co-stimulatory molecule that is in preclinical stage. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase I clinical trials for the treatment of diabetic macular edema. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and CRUK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Barchart technical indicators:

• 100% technical buy signals
• 86.35+ Weighted Alpha
• 94.52% gain in the last year
• Trend Spotter buy signal
• Above its 20, 50 and 100 day moving averages
• 10 new highs and up 19.34% in the last month
• Relative Strength Index 75.75%
• Technical support level at 34.68
• Recently traded at 35.20 with a 50 day moving average of 30.99

Fundamental factors:

• Market Cap $841 million
• Although analysts predict deceasing Revenue and Earnings they are willing to recommend anything in the medical sector
• Wall Street analysts issued 4 strong buy and 5 buy recommendation on the stock
• The individual investors on Motley Fool have not yet discovered this stock and rarely follow ADRs
• 1,450 investors are monitoring the stock on Seeking Alpha